Golimumab for non-radiographic axial spondyloarthritis, October 2021
Page last updated: 24 March 2022
Drug utilisation sub-committee (DUSC)
October 2021
Abstract
Purpose
To compare the predicted and actual utilisation of golimumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in the first 24 months of Pharmaceutical Benefits Scheme (PBS) listing.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Golimumab was first listed on the PBS 1 August 2010, and first listed for nr-axSpA on 1 December 2018.
Data Source / methodology
Data were extracted from the Services Australia Supplied Prescription database.
Key Findings
- There were 225 and 413 patients treated with golimumab for nr-axSpA during the first and second year of listing respectively, which was lower than predicted.
- There were 1,013 and 2,331 prescriptions dispensed for golimumab for nr-axSpA during the first and second year of listing respectively, which was lower than predicted.
- The most common age group in patients beginning golimumab treatment for nr-axSpA treatment were those aged between 30-35 years old with 54% of initiating patients being female.
- Other biologic therapies for nr-axSpA, such as certolizumab pegol and secukinumab, are gaining market share.
